Clinical Correlates of Serum Pigment Epithelium-derived Factor in Type 2 Diabetes Patients

Overview

Journal J Diabetes Complications

Specialty Endocrinology

Date 2014 Feb 25

PMID 24560422

Citations 13

Authors

Alicia J Jenkins

Dongxu Fu

Madona Azar

Julie A Stoner

Derrick G Kaufman

Sarah Zhang

Richard L Klein

Maria F Lopes-Virella

Jian-Xing Ma

Timothy J Lyons

Affiliations

Soon will be listed here.

Abstract

Aim: To determine if serum pigment epithelium-derived factor (PEDF) levels in Type 2 diabetes are related to vascular risk factors and renal function.

Methods: PEDF was quantified by ELISA in a cross-sectional study of 857 male Veterans Affairs Diabetes Trial (VADT) subjects, and associations with cardiovascular risk factors and renal function were determined. In a subset (n=246) in whom serum was obtained early in the VADT (2.0±0.3 years post-randomization), PEDF was related to longitudinal changes in renal function over 3.1 years.

Results: Cross-sectional study: In multivariate regression models, PEDF was positively associated with serum triglycerides, waist-to-hip ratio, serum creatinine, use of ACE inhibitors or angiotensin receptor blockers, and use of lipid-lowering agents; it was negatively associated with HDL-C (all p<0.05). Longitudinal study: PEDF was not associated with changes in renal function over 3.1 years (p>0.09).

Conclusions: Serum PEDF in Type 2 diabetic men was cross-sectionally associated with dyslipidemia, body habitus, use of common drugs for blood pressure and dyslipidemia, and indices of renal function; however, PEDF was not associated with renal decline over 3.1years.

Citing Articles

Haptoglobin phenotype and levels in type 2 diabetes and effects of fenofibrate.

Januszewski A, Young H, Ong K, Li L, OConnell R, Lyons T J Diabetes Investig. 2024; 15(11):1663-1668.

PMID: 39171747 PMC: 11527820. DOI: 10.1111/jdi.14290.

Circulating Sphingolipids in Insulin Resistance, Diabetes and Associated Complications.

Hammad S, Lopes-Virella M Int J Mol Sci. 2023; 24(18).

PMID: 37762318 PMC: 10531201. DOI: 10.3390/ijms241814015.

Triglyceride-glucose index is prospectively associated with chronic kidney disease progression in Type 2 diabetes - mediation by pigment epithelium-derived factor.

Low S, Pek S, Moh A, Ang K, Khoo J, Shao Y Diab Vasc Dis Res. 2022; 19(4):14791641221113784.

PMID: 35938490 PMC: 9364218. DOI: 10.1177/14791641221113784.

Serum pigment epithelium-derived factor: Relationships with cardiovascular events, renal dysfunction, and mortality in the Veterans Affairs Diabetes Trial (VADT) cohort.

Hunt K, Jenkins A, Fu D, Stevens D, Ma J, Klein R J Diabetes Complications. 2019; 33(10):107410.

PMID: 31434620 PMC: 6786884. DOI: 10.1016/j.jdiacomp.2019.107410.

Endogenous Antiangiogenic Factors in Chronic Kidney Disease: Potential Biomarkers of Progression.

Tanabe K, Sato Y, Wada J Int J Mol Sci. 2018; 19(7).

PMID: 29937525 PMC: 6073618. DOI: 10.3390/ijms19071859.

References

Wang F, Ma X, Zhou M, Pan X, Ni J, Gao M . Serum pigment epithelium-derived factor levels are independently correlated with the presence of coronary artery disease. Cardiovasc Diabetol. 2013; 12:56. PMC: 3626632. DOI: 10.1186/1475-2840-12-56. View

Chen H, Zheng Z, Li R, Lu J, Bao Y, Ying X . Urinary pigment epithelium-derived factor as a marker of diabetic nephropathy. Am J Nephrol. 2010; 32(1):47-56. DOI: 10.1159/000314326. View

Bohm A, Ordelheide A, Machann J, Heni M, Ketterer C, Machicao F . Common genetic variation in the SERPINF1 locus determines overall adiposity, obesity-related insulin resistance, and circulating leptin levels. PLoS One. 2012; 7(3):e34035. PMC: 3311576. DOI: 10.1371/journal.pone.0034035. View

Maeda S, Matsui T, Takeuchi M, Yoshida Y, Yamakawa R, Fukami K . Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis. Pharmacol Res. 2010; 63(3):241-8. DOI: 10.1016/j.phrs.2010.11.008. View

Akin S, Yazgan Aksoy D, Cinar N, Aydin K, Karaagaoglu E, Ariyurek M . Pigment epithelium-derived factor increases in type 2 diabetes after treatment with metformin. Clin Endocrinol (Oxf). 2012; 77(6):852-6. DOI: 10.1111/j.1365-2265.2012.04341.x. View

Ide Y, Matsui T, Ishibashi Y, Takeuchi M, Yamagishi S . Pigment epithelium-derived factor inhibits advanced glycation end product-elicited mesangial cell damage by blocking NF-kappaB activation. Microvasc Res. 2010; 80(2):227-32. DOI: 10.1016/j.mvr.2010.03.015. View

Mohan N, Monickaraj F, Balasubramanyam M, Rema M, Mohan V . Imbalanced levels of angiogenic and angiostatic factors in vitreous, plasma and postmortem retinal tissue of patients with proliferative diabetic retinopathy. J Diabetes Complications. 2012; 26(5):435-41. DOI: 10.1016/j.jdiacomp.2012.05.005. View

Zhu X, Zou H . PEDF in diabetic retinopathy: a protective effect of oxidative stress. J Biomed Biotechnol. 2012; 2012:580687. PMC: 3335847. DOI: 10.1155/2012/580687. View

Park K, Jin J, Hu Y, Zhou K, Ma J . Overexpression of pigment epithelium-derived factor inhibits retinal inflammation and neovascularization. Am J Pathol. 2011; 178(2):688-98. PMC: 3070578. DOI: 10.1016/j.ajpath.2010.10.014. View

10.

Golden S, Brown A, Cauley J, Chin M, Gary-Webb T, Kim C . Health disparities in endocrine disorders: biological, clinical, and nonclinical factors--an Endocrine Society scientific statement. J Clin Endocrinol Metab. 2012; 97(9):E1579-639. PMC: 3431576. DOI: 10.1210/jc.2012-2043. View

11.

Chung C, Doll J, Stellmach V, Gonzales J, Surapureddi S, Cornwell M . Pigment epithelium-derived factor is an angiogenesis and lipid regulator that activates peroxisome proliferator-activated receptor alpha. Adv Exp Med Biol. 2008; 617:591-7. DOI: 10.1007/978-0-387-69080-3_61. View

12.

Sabater M, Moreno-Navarrete J, Ortega F, Pardo G, Salvador J, Ricart W . Circulating pigment epithelium-derived factor levels are associated with insulin resistance and decrease after weight loss. J Clin Endocrinol Metab. 2010; 95(10):4720-8. DOI: 10.1210/jc.2010-0630. View

13.

Yamagishi S, Matsui T, Kawaguchi T, Sata M . Pathophysiological role of pigment epithelium-derived factor (PEDF) in hepatic disorders. Curr Med Chem. 2010; 17(19):1995-2000. DOI: 10.2174/092986710791233670. View

14.

Yamagishi S, Matsui T, Nakamura K, Ueda S, Noda Y, Imaizumi T . Pigment epithelium-derived factor (PEDF): its potential therapeutic implication in diabetic vascular complications. Curr Drug Targets. 2008; 9(11):1025-9. DOI: 10.2174/138945008786786154. View

15.

Tombran-Tink J, Barnstable C . PEDF: a multifaceted neurotrophic factor. Nat Rev Neurosci. 2003; 4(8):628-36. DOI: 10.1038/nrn1176. View

16.

Tahara N, Yamagishi S, Tahara A, Takeuchi M, Imaizumi T . Serum levels of pigment epithelium-derived factor, a novel marker of insulin resistance, are independently associated with fasting apolipoprotein B48 levels in humans. Clin Biochem. 2012; 45(16-17):1404-8. DOI: 10.1016/j.clinbiochem.2012.07.095. View

17.

Yamagishi S, Matsui T, Nakamura K . Atheroprotective properties of pigment epithelium-derived factor (PEDF) in cardiometabolic disorders. Curr Pharm Des. 2009; 15(9):1027-33. DOI: 10.2174/138161209787581940. View

18.

Ogata N, Matsuoka M, Matsuyama K, Shima C, Tajika A, Nishiyama T . Plasma concentration of pigment epithelium-derived factor in patients with diabetic retinopathy. J Clin Endocrinol Metab. 2007; 92(3):1176-9. DOI: 10.1210/jc.2006-2249. View

19.

Jenkins A, Zhang S, Rowley K, Karschimkus C, Nelson C, Chung J . Increased serum pigment epithelium-derived factor is associated with microvascular complications, vascular stiffness and inflammation in Type 1 diabetes. Diabet Med. 2007; 24(12):1345-51. DOI: 10.1111/j.1464-5491.2007.02281.x. View

20.

Ishibashi Y, Matsui T, Ohta K, Tanoue R, Takeuchi M, Asanuma K . PEDF inhibits AGE-induced podocyte apoptosis via PPAR-gamma activation. Microvasc Res. 2012; 85:54-8. DOI: 10.1016/j.mvr.2012.10.007. View